MHH Logo




Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K.

Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study.

J Neurol Sci. 2002 Dec 15;205(1):59-63.



Bigalke H.

The pharmacology of botulinum toxin

Med Monatsschr Pharm. 2002 Sep;25(9):305-8.



Birklein F, Walther D, Bigalke H, Winterholler M, Erbguth F.

Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.

Ann Neurol. 2002 Jul;52(1):68-73.



Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H.

Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?

Eur Neurol. 2002;47(2):118-21.



Wilde C, Barth H, Sehr P, Han L, Schmidt M, Just I, Aktories K.

Interaction of the Rho-ADP-ribosylating C3 exoenzyme with RalA.

J Biol Chem. 2002 Apr 26;277(17):14771-6. Epub 2002 Feb 14.



Wilde C, Just I, Aktories K.

Structure-function analysis of the Rho-ADP-ribosylating exoenzyme C3stau2 from Staphylococcus aureus.

Biochemistry. 2002 Feb 5;41(5):1539-44.



Schirmer J, Just I, Aktories K.

The ADP-ribosylating mosquitocidal toxin from Bacillus sphaericus: proteolytic activation, enzyme activity, and cytotoxic effects.

J Biol Chem. 2002 Apr 5;277(14):11941-8. Epub 2002 Jan 25.



Dressler D, Bigalke H.

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy.

Mov Disord. 2002 Jan;17(1):170-3.